Interim STOP-HS1/2 data show povorcitinib yielded modest lesion reductions, improved pain scores, and some higher-threshold clinical responses in patients with hidradenitis suppurativa.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/phase-3-data-put-povorcitinib-hs-radar-2025a1000p7u?src=rss
Author :
Publish date : 2025-09-22 18:22:00
Copyright for syndicated content belongs to the linked Source.
